Table 2. Current selected clinical trials on NB.
| Clinical trials | Interventions | URL |
|---|---|---|
| 124I-Metaiodobenzylguanidine (MIBG) PET/CT Diagnostic Imaging and Dosimetry for Patients With Neuroblastoma: A Pilot Study | Radiation: 124I-MIBG (no-carrier added) Radiation: 124I-MIBG (carrier added) | https://ClinicalTrials.gov/show/NCT01583842 |
| European Low and Intermediate Risk Neuroblastoma Protocol (low and intermediate pediatric NB and neonatal suprarenal masses) | Drug: chemotherapy | https://ClinicalTrials.gov/show/NCT01728155 |
| Phase II Study of Proton Radiation Therapy for Neuroblastoma | Radiation: proton beam radiation therapy | https://ClinicalTrials.gov/show/NCT02112617 |
| Immunomonitoring of Children With Neuroblastoma | Immunological analyses | https://ClinicalTrials.gov/show/NCT01295762 |
| Bivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral β-glucan for High-Risk Neuroblastoma | Biological: adjuvant OPT-821 in a vaccine containing two antigens (GD2L and GD3L) covalently linked to KLH | https://ClinicalTrials.gov/show/NCT00911560 |
| Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma | Laboratory biomarker analysis; cytology specimen collection procedure | https://ClinicalTrials.gov/show/NCT00904241 |
| Multimodal Molecular Targeted Therapy to Treat Relapsed or Refractory High-risk Neuroblastoma | Drug: dasatinib Drug: rapamycin Drug: irinotecan Drug: temozolomide Drug: irinotecan Drug: temozolomide | https://ClinicalTrials.gov/show/NCT01467986 |
| Study of DNA in Blood Samples From Patients With Neuroblastoma | Laboratory biomarker analysis Genetic: polymerase chain reaction Genetic: polyacrylamide gel electrophoresis Genetic: DNA analysis | https://ClinicalTrials.gov/show/NCT00898391 |
| Monitor Response to Treatment in Neuroblastoma Using 3&Apos;-Deoxy-3&Apos;-Fluorothymidine-Positron Emission Tomography (FLT-PET) | Device: FLT-PET | https://ClinicalTrials.gov/show/NCT01308905 |
| Expanded Access Study of Fenretinide Lym-X-Sorb Plus Ketoconazole in Neuroblastoma | Drug: fenretinide Lym-X-Sorb oral powder Drug: ketoconazole | https://ClinicalTrials.gov/show/NCT02075177 |
| Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults with Neuroblastoma and Osteosarcoma | Biological: IL-2 Biological: GD2Bi-aATC Biological: GM-CSF Other: laboratory evaluations of immune responses | https://ClinicalTrials.gov/show/NCT02100930 |
| Anti-GD2 3F8 Monoclonal Antibody and GM-CSF for High-Risk Neuroblastoma | Biological: anti-GD2 3F8 monoclonal antibody Drug: GM-CSF (granulocyte-macrophage colony-stimulating factor) Drug: oral isotretinoin | https://ClinicalTrials.gov/show/NCT02100930 |
| Fenretinide Lym-X-Sorb+Ketoconazole+Vincristine for Recurrent or Resistant Neuroblastoma | Drug: fenretinide/LXS oral powder Drug: ketoconazole Drug: vincristine | https://ClinicalTrials.gov/show/NCT02163356 |
| Pilot Study of Activated T-Cell Therapy for Refractory/Relapsed Neuroblastoma | Biological: activated T lymphocyte | https://ClinicalTrials.gov/show/NCT01802138 |
| 3rd Generation GD-2 Chimeric Antigen Receptor and iCaspase Suicide Safety Switch, Neuroblastoma, GRAIN | Genetic: iC9-GD2 T-cell lymphocytes – frozen cells Genetic: iC9-GD2 T-cell lymphocytes – fresh cells Drug: cyclophosphamide Drug: fludarabine Drug: pembrolizumab | https://ClinicalTrials.gov/show/NCT01822652 |
All trials above are recruiting and no results are available yet. From www.clinicaltrials.gov